Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMM

Authors

Institutions

Publication Details

Journal
The Breast
Published
2025-11-21
DOI
https://doi.org/10.1016/j.breast.2025.104648
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMM

Julien Grenier, Jean‐Yves Pierga, Philippe Toussaint, F. Viret et al.
The Breast
Breast Cancer Treatment Studies
article

Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMM

Julien Grenier, Jean‐Yves Pierga, Philippe Toussaint, F. Viret, David Pérol, Jean‐Philippe Spano, Olivier Trédan, Louis Doublet, Jean‐Sébastien Frenel, Thomas Bachelot, Sylvie Chabaud, Christelle Lévy, Yann Molin, Olfa Derbel, D. Loirat, Anne Patsouris, Pierre-Etienne Heudel, Gwenaële Garin, Christelle Jouannaud, Thierry Petit, Laura Mansi, Jean Marc Ferrero, Aurélien Robert
article en

Abstract

No abstract available for this paper.
The BreastVol. 85
Université Paris Cité (FR), Sorbonne Université (FR), Centre Hospitalier Universitaire de Besançon (FR), Institut de Cancérologie Strasbourg (FR), Centre François Baclesse (LU), Centre Léon Bérard (FR), Institut de Cancérologie de l'Ouest (FR), Pôle Léonard de Vinci (FR), Pitié-Salpêtrière Hospital (FR), Centre François Baclesse (FR), Hôpital Privé Jean Mermo (FR), Centre Hospitalier de Valence (FR), Institut Paoli-Calmettes (FR), Centre Antoine Lacassagne (FR), Hôpital Charles-Foix (FR), Institut Jean Godinot (FR), Institut Sainte Catherine (FR), Institut Curie (FR)
Openalex Percentile: Top 54%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.